Tender Details

Country: USA
Summary: Dod Amyotrophic Lateral Sclerosis, Therapeutic Development Award
UST Ref No: 117933280
Deadline: 27 Aug 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: USD 9800000
Notice Type: Tender
Document Ref. No.: HT942525ALSRPTDA
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Summary: The Fiscal Year 2025 (Fy25) Amyotrophic Lateral Sclerosis Research Program (Alsrp) Therapeutic Development Award (Tda) Supports Research Ranging From Preclinical Validation Of Therapeutic Leads Through Food And Drug Administration (Fda) Investigational New Drug (Ind)-Enabling Studies. The Proposed Studies Are Expected To Be Empirical In Nature And Product Driven. Applicants With Limited Amyotrophic Lateral Sclerosis (Als) Experience Are Strongly Encouraged To Include Collaborators With Substantial Experience In The Relevant Als Model Systems, Endpoints, And Pathophysiology.Applications Supported By This Award Must Begin With Lead Compounds In Hand And Must Already Demonstrate Proof-Of-Concept Efficacy Data In At Least One Appropriate Preclinical Model System Of Als, Including Whole Animal And Cellular Model Systems. Distinctive Features: Mechanism-Specific, Predictive/Cohort-Selective, Target Engagement, And Pharmacodynamic Biomarker Development, In Parallel To The Main Therapeutic Effort, Is A Critical Component Of The Fy25 Alsrp Therapeutic Development Award. If Appropriate Mechanism-Specific Biomarkers Are Already Available Or Currently In Development, How The Existing Biomarkers Will Improve Trial Design, Patient Selection, And Efficiency Or Interpretation Of The Proposed Als Therapeutic Approach Must Be Apparent In The Application. Development Of Biomarkers For The Purposes Of Diagnosis, Prognosis, Or Measurement Of General Disease Progression Without Considerat...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Dod Amyotrophic Lateral Sclerosis, Therapeutic Development Award - USA Tender

The DEPT. OF THE ARMY -- USAMRAA, a Government sector organization in USA, has announced a new tender for Dod Amyotrophic Lateral Sclerosis, Therapeutic Development Award. This tender is published on USARFP under UST Ref No: 117933280 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-08-27.

The estimated tender value is USD 9800000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.